Dr. Raphael Mechoulam Explains Latest Findings

Raphael Mechoulam, His latest discovery, also known as the “father of cannabis research,” cannabidiol acid methyl ester (EPM301) was revealed just a few months ago. The introduction of this new patented compound, a synthetic, fully stable acid-based cannabinoid molecule, has caused a wave of excitement over the future of medicinal cannabis.

The compound in question was presented to the world in partnership with EPM, a US-based global biotechnology company that aims to bridge the gap between the cannabis and pharmaceutical industries.

< position="inread" progressive="" ad-id="article-0-inread" aria-hidden="true" role="presentation"/>

In a recent exclusive conversation, CEOs Reshef Swisa and Dr. Mechoulam share the journey history behind this innovative process and the importance of developing the use of CBD as a drug. did.

Meet EPM301

“EPM has developed a method to treat the original substance of cannabis,” explained the professor. “So, while everyone is talking about THC and CBD, these cannabinoids are actually secondary substances. They only appear later in the plant.

“There are acids that originally appear in plants, and those acids are these mysterious worlds of compounds that are much more powerful than cannabinoids,” he added.

See also University of Toronto, Canadian Biotechnology Company Collaborate on Cannabinoid-Based COVID-19 Treatment

However, these cannabidiol acids are unstable and therefore useless for drug development. Until now it is.

A recent revelation of Mechoulam stems from the development of a method that allows the acid to be modified in a way that keeps it stable enough to allow its extensive use. The professor explained that this opens the door to further pharmaceutical experiments.

“We took cannabidiol acid and stabilized it with a simple chemical procedure called esterification. After that, the compound is stable,” explained Swisa.

The team then “initiated a study of the activity of this compound… and discovered that this particular compound caused anxiety and nausea depression,” he continued, which states that the chemotherapy cancer As a patient with IBD (Inflammatory Bowel Disease) or psoriasis, he added, it could make a huge difference to patients.

Innovate at 88

It has long been known that CBD and THC help relieve symptoms in a variety of conditions, from inflammation and anxiety to depression and nausea.

See also UNM Study: Cannabis Is Effective In Treating Depression And Improves Mental Health

In fact, Mechoulam was probably the most important discipline in the 1960s to uncover the active ingredients of cannabis plants, and his work at the Weisman Institute led to the discovery of the human endocannabinoid system, leading to the “Father Cannabis Study”. of.”

However, according to the latest findings of an 88-year-old researcher, cannabidiol acid is a much more potent compound than CBD and THC, with no known adverse effects.

“Some illnesses need new drugs, some available may be quite good, but eventually cause side effects,” he said, most non-natural Refers to the drug, which is at best semi-synthetic.

“We have two groups of compounds today that need alternatives. These are steroids and opioids. Cannabis believes it has the ability to introduce alternatives into these families. .”

Alternatives to steroids and opioids

While CBD has been considered an alternative to addictive prescription drugs over the last few years, EPM’s patents on the use of cannabidiolate show that these drugs it can In essence, it can be replaced without significantly changing efficiency.

“We are comparing our compounds not only with cannabinoids, but also with existing drugs that are being applied today,” Mechoulam explained. “So at IBD, for example, we compared our mixture to two conventional products: one is prednisone (a steroid), one is a biologic, and either way, We were able to prove that the activity of the compound is very similar to the general one.”

Researchers are optimistic about the future.

“I sincerely hope that within the next few years, the cannabidiol acid derivatives will go on the market in parallel with CBD itself.”

See also The Tosh Family: Torn By Injustice, United By Love (And Cannabis)

But he also cautioned against the importance of properly classifying and regulating drugs for medical use to avoid unwanted side effects.

“Companies need to be careful when claiming a cure by taking a compound. In order to be linguistically consistent, they must do so according to regulations because people use recreational and It’s because you confuse use and don’t necessarily want a particular indication or a particular medication.”